Yin J - Search Results

1

SerpinB3/4 Expression Is Associated with Poor Prognosis in Patients with Cholangiocarcinoma.

Martini A, Prasai K, Zemla TJ, Ahmed FY, Elnagar MB, Giama NH, Guzzardo V, Biasiolo A, Fassan M, Yin J, Pontisso P, Roberts LR. Martini A, et al. Among authors: yin j. Cancers (Basel). 2024 Jan 3;16(1):225. doi: 10.3390/cancers16010225. Cancers (Basel). 2024. PMID: 38201652 Free PMC article.

2

Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling.

Wang H, Hou W, Perera A, Bettler C, Beach JR, Ding X, Li J, Denning MF, Dhanarajan A, Cotler SJ, Joyce C, Yin J, Ahmed F, Roberts LR, Qiu W. Wang H, et al. Among authors: yin j. Cell Rep. 2021 Feb 23;34(8):108765. doi: 10.1016/j.celrep.2021.108765. Cell Rep. 2021. PMID: 33626345 Free PMC article.

3

Histone Deacetylase Sirtuin 1 Promotes Loss of Primary Cilia in Cholangiocarcinoma.

Pant K, Peixoto E, Richard S, Biswas A, O'Sullivan MG, Giama N, Ha Y, Yin J, Carotenuto P, Salati M, Ren Y, Yang R, Franco B, Roberts LR, Gradilone SA. Pant K, et al. Among authors: yin j. Hepatology. 2021 Dec;74(6):3235-3248. doi: 10.1002/hep.32080. Epub 2021 Sep 27. Hepatology. 2021. PMID: 34322899

4

Morphological heterogeneity in beta-catenin-mutated hepatocellular carcinomas: implications for tumor molecular classification.

Torbenson M, McCabe CE, O'Brien DR, Yin J, Bainter T, Tran NH, Yasir S, Chen ZE, Dhanasekaran R, Ahn KS, Roberts LR, Wang C. Torbenson M, et al. Among authors: yin j. Hum Pathol. 2022 Jan;119:15-27. doi: 10.1016/j.humpath.2021.09.009. Epub 2021 Sep 27. Hum Pathol. 2022. PMID: 34592239 Free PMC article.

5

PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and ⁶⁸ Ga-PSMA-11 PET Using Cyclotron-Produced ⁶⁸ Ga.

Thompson SM, Suman G, Torbenson MS, Chen ZE, Jondal DE, Patra A, Ehman EC, Andrews JC, Fleming CJ, Welch BT, Kurup AN, Roberts LR, Watt KD, Truty MJ, Cleary SP, Smoot RL, Heimbach JK, Tran NH, Mahipal A, Yin J, Zemla T, Wang C, Fogarty Z, Jacobson M, Kemp BJ, Venkatesh SK, Johnson GB, Woodrum DA, Goenka AH. Thompson SM, et al. Among authors: yin j. Hepatol Commun. 2022 May;6(5):1172-1185. doi: 10.1002/hep4.1861. Epub 2021 Nov 15. Hepatol Commun. 2022. PMID: 34783177 Free PMC article.

6

Evaluating the Significance of Pancreatobiliary Fluorescence In Situ Hybridization Polysomy on Prognosis in De Novo Cholangiocarcinoma.

Ji H, Barr Fritcher EG, Yin J, Bainter TM, Zemla TJ, Gores GJ, Halling KC, Kipp BR, Roberts LR. Ji H, et al. Among authors: yin j. Clin Transl Gastroenterol. 2022 Oct 1;13(10):e00523. doi: 10.14309/ctg.0000000000000523. Clin Transl Gastroenterol. 2022. PMID: 36000989 Free PMC article.

7

Mixed Acinar Neuroendocrine Carcinoma of the Pancreas: Comparative Population-Based Epidemiology of a Rare and Fatal Malignancy in The United States.

Abdelrahman AM, Yin J, Alva-Ruiz R, Yonkus JA, Leiting JL, Lynch IT, Fogliati A, Campbell NA, Carlson DM, Roberts LR, Gores GJ, Smoot RL, Graham RP, Halfdanarson TR, Truty MJ. Abdelrahman AM, et al. Among authors: yin j. Cancers (Basel). 2023 Jan 30;15(3):840. doi: 10.3390/cancers15030840. Cancers (Basel). 2023. PMID: 36765798 Free PMC article.

8

The NAMPT Inhibitor FK866 in Combination with Cisplatin Reduces Cholangiocarcinoma Cells Growth.

Pant K, Richard S, Peixoto E, Yin J, Seelig DM, Carotenuto P, Salati M, Franco B, Roberts LR, Gradilone SA. Pant K, et al. Among authors: yin j. Cells. 2023 Feb 28;12(5):775. doi: 10.3390/cells12050775. Cells. 2023. PMID: 36899911 Free PMC article.

9

Impact of perioperative chemotherapy on survival in patients with cholangiocarcinoma undergoing curative resection.

Hassan H, Chakrabarti S, Zemla T, Yin J, Wookey V, Prasai K, Abdellatief A, Katta R, Tran N, Jin Z, Cleary S, Roberts L, Mahipal A. Hassan H, et al. Among authors: yin j. Eur J Surg Oncol. 2023 Nov;49(11):106994. doi: 10.1016/j.ejso.2023.106994. Epub 2023 Jul 27. Eur J Surg Oncol. 2023. PMID: 37524649 Free PMC article.

10

Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort.

Emiloju OE, Yin J, Koubek E, Reid JM, Borad MJ, Lou Y, Seetharam M, Edelman MJ, Sausville EA, Jiang Y, Kaseb AO, Posey JA, Davis SL, Gores GJ, Roberts LR, Takebe N, Schwartz GK, Hendrickson AEW, Kaufmann SH, Adjei AA, Hubbard JM, Costello BA. Emiloju OE, et al. Among authors: yin j. Invest New Drugs. 2024 Feb;42(1):127-135. doi: 10.1007/s10637-024-01420-8. Epub 2024 Jan 25. Invest New Drugs. 2024. PMID: 38270822 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

12,215 results

Search Page

Filters